These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 33781531)

  • 1. Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
    Balaguer-Rosello A; Piñana JL; Bataller L; Montoro J; Romero S; Navarro I; Lorenzo I; Andreu R; Guerreiro M; Aguilar C; Gorriz D; Dominguez L; de la Puerta R; Gómez I; Solves P; Jarque I; Sanz MÁ; Sanz G; Sanz J
    Transplant Cell Ther; 2021 Mar; 27(3):261.e1-261.e7. PubMed ID: 33781531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review.
    Su YY; Yu YF; Yan ZY; Zhao YJ; Lou JW; Xue F; Xu M; Feng Q; Ji XB; Dong XY; Wang W; Liu CF; Peng J; Liu XG
    Diagn Pathol; 2024 Sep; 19(1):122. PubMed ID: 39244586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation.
    Liu L; Zhang X; Feng S
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1341-1349. PubMed ID: 29530767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
    Chen DB; Song QJ; Chen YX; Chen YH; Shen DH
    Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.
    Liu QF; Ling YW; Fan ZP; Jiang QL; Sun J; Wu XL; Zhao J; Wei Q; Zhang Y; Yu GP; Wu MQ; Feng R
    Transpl Infect Dis; 2013 Aug; 15(4):379-92. PubMed ID: 23692640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.
    Chen DB; Liu XY; Kong FZ; Jiang Q; Shen DH
    J Clin Pathol; 2021 Nov; 74(11):697-703. PubMed ID: 34011618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
    Romero S; Montoro J; Guinot M; Almenar L; Andreu R; Balaguer A; Beneyto I; Espí J; Gómez-Codina J; Iacoboni G; Jarque I; López-Andújar R; Mayordomo-Aranda E; Montalar J; Pastor A; Pastor M; Piñana JL; Rojas-Ferrer N; Sánchez-Lázaro I; Sandoval J; Sanz G; Sanz MÁ; Solé A; Sanz J
    Leuk Lymphoma; 2019 Jan; 60(1):142-150. PubMed ID: 29966464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients.
    Barker JN; Martin PL; Coad JE; DeFor T; Trigg ME; Kurtzberg J; Weisdorf DJ; Wagner J
    Biol Blood Marrow Transplant; 2001; 7(7):395-9. PubMed ID: 11529490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of quantitative EBV DNA measurements in cerebrospinal fluid for diagnosis and monitoring of treatment of central nervous system EBV-associated post-transplant lymphoproliferative disorder after allogenic hematopoietic stem cell transplantation.
    Bocian J; Januszkiewicz-Lewandowska D
    Ann Transplant; 2014 May; 19():253-6. PubMed ID: 24866354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
    Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT
    Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
    Solano C; Mateo EM; Pérez A; Talaya A; Terol MJ; Albert E; Giménez E; Vinuesa V; Piñana JL; Boluda JCH; Navarro D
    J Clin Virol; 2017 Dec; 97():26-32. PubMed ID: 29096390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
    Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
    Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases.
    Sanz J; Arango M; Senent L; Jarque I; Montesinos P; Sempere A; Lorenzo I; Martín G; Moscardó F; Mayordomo E; Salavert M; Cañigral C; Boluda B; Salazar C; López-Hontangas JL; Sanz MA; Sanz GF
    Bone Marrow Transplant; 2014 Mar; 49(3):397-402. PubMed ID: 24292521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP
    Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651
    [No Abstract]   [Full Text] [Related]  

  • 20. [Dynamic monitoring of plasma Epstein-Barr Virus DNA load can predict the occurrence of lymphoproliferative disorders after haploidentical hematopoietic stem cell transplantation].
    Chen J; Sun YQ; Xu LP; Zhang XH; Liu KY; Mo XD; Cheng YF; Huang XJ; Wang Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):284-288. PubMed ID: 37356996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.